Table 3.
The correlation between DMDs and the risk of hospitalization.
| Hospitalized (n) | Not hospitalized (n) | P-Value | |
|---|---|---|---|
| Rituximab | 12 | 26 | 0.15 |
| Natalizumab | 0 | 2 | 0.40 |
| Ocrelizumab | 1 | 0 | 0.08 |
| Fingolimod | 1 | 3 | 1 |
| DMF | 0 | 2 | 0.40 |
| Glatiramer Acetate | 0 | 5 | 0.17 |
| IFN Beta 1A SC | 0 | 5 | 0.17 |
| IFN Beta 1A IM | 0 | 5 | 0.17 |
| Azathioprin | 1 | 0 | 0.08 |
| No medication | 2 | 0 | 0.012 fisher exact; 0.059 |
| OTHER MEDICATIONS | 0 | 3 | FISHER ECAT; 0.56 |
DMF: dimethylformamide; IFN-β 1α IM: interferon-β 1α intramuscular; interferon-β 1α subcutaneous.